The trial assessed the safety and efficacy of bexarotene, which is licensed for the treatment of cutaneous T cell lymphoma, as a remyelinating therapy in people with relapsing-remitting MS. The 52 randomised participants were aged 18-50 years, had an EDSS score of 6 or less and at least 5 MRI brain lesions, and were stable on dimethyl fumarate for at least 6 months. They were randomised 1:1 to bexarotene 300 mg/m2 or placebo for 6 months. The primary efficacy endpoint was change in magnetisation transfer ratio (MTR) of those lesions with the lowest tissue integrity at baseline, that is those with MTR values below the “within-patient” median (the submedian). Analysis was by intention to treat.
The primary efficacy outcome was not met. There was no significant difference in mean submedian lesion MTR change. This difference, adjusted for baseline MTR, EDSS, age, gender, and site, was 0.16 pu (0.25 pu in the bexarotene group vs 0.09 pu in the placebo group; P=0.54). In an exploratory analysis at lesion level, the treatment difference in submedian lesions was significantly greater than in supermedian lesions (P=0.001-0.007). This suggests a biological effect of bexarotene on MTR which depends on baseline lesional MTR. When lesions were divided by location, there were statistically significant treatment differences in cortical grey matter lesions, deep grey matter lesions, and brainstem lesions. Furthermore, bexarotene reduced full field visual evoked potential (VEP) latency versus placebo in all eyes and in the 52 eyes with delayed VEPs at baseline.
All 26 patients in the bexarotene group experienced adverse effects: 6.12 on average. Patients in the placebo group experienced on average 1.63 adverse events. In the experimental group, 100% experienced hypothyroidism, and 92% hypertriglyceridaemia, while 50% had rash and 38% neutropenia. In the bexarotene and placebo group, there were 0 and 1 serious adverse events, respectively.
- Brown J, et al. Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis. MSVirtual 2020, LB01.02
Posted on
Previous Article
« Gut dysbiosis in NMOSD promotes CNS autoimmunity Next Article
Gold nanocrystals may improve brain metabolic profile »
« Gut dysbiosis in NMOSD promotes CNS autoimmunity Next Article
Gold nanocrystals may improve brain metabolic profile »
Table of Contents: MS Virtual 2020
Featured articles
Registry participation can enhance quality of rheumatology care
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
T2T approach in women with RA associated with increased fertility
Positive results for vagus nerve stimulation in RA
Machine learning to aid evaluation of ANA pattern and titer
ICI therapy does not increase mortality risk in patients with pre-existing autoimmune disease
Registry participation can enhance quality of rheumatology care
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
June 16, 2021
MS therapies influence COVID-19 severity
December 20, 2022
Humoral and cellular immune responses after SARS-CoV-2 vaccination
December 9, 2021
The role of astrocyte phenotypes in acute MS lesions
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com